We are live on ! Find out more
ZYNE

Zynerba Pharmaceuticals, Inc
ZYNE

Delisted

ZYNE was delisted on the 10th of October, 2023.

Back to rankings

66 hedge funds and large institutions have $77M invested in Zynerba Pharmaceuticals, Inc in 2017 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 20

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

10% more funds holding

Funds holding: 60 → 66 (+6)

9% more capital invested

Capital invested by funds: $70.5M → $77M (+$6.53M)

41% less call options, than puts

Call options by funds: $17.1M | Put options by funds: $28.8M

Holders
66
Holders Change
+6
Holders Change %
+10%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
19
Reduced
15
Closed
20
Calls
$17.1M
Puts
$28.8M
Net Calls
-$11.7M
Net Calls Change
-$14.1M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$9.17M
2
JP Morgan Chase
JP Morgan Chase
New York
+$6.48M
3
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
+$6.03M
4
Deutsche Bank
Deutsche Bank
Germany
+$4.44M
5
Citigroup
Citigroup
New York
+$4.38M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$10.1M
2
PA
Perceptive Advisors
New York
-$5M
3
SFM
Sphera Funds Management
Israel
-$2.01M
4
MWA
Marshall Wace Asia
Hong Kong
-$1.65M
5
MWNA
Marshall Wace North America
New York
-$1.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
51
ALPS Advisors
Colorado
$12K +$238K +11,959 New
Barclays
52
Barclays
United Kingdom
$10K -$194K -9,774 -94%
GT
53
Glenmede Trust
Pennsylvania
$10K – – –
GWM
54
Geneos Wealth Management
Colorado
$8K -$9.94K -500 -50%
KF
55
Krilogy Financial
Missouri
$4K +$4.61K +232 New
Bank of America
56
Bank of America
North Carolina
$3K -$83.8K -4,216 -96%
NFG
57
Next Financial Group
Texas
$3K – – –
Bank of Montreal
58
Bank of Montreal
Ontario, Canada
$3K +$3.66K +184 New
KTC
59
Kistler-Tiffany Companies
Pennsylvania
$2K – – –
PA
60
Parallel Advisors
California
$2K – – –
Royal Bank of Canada
61
Royal Bank of Canada
Ontario, Canada
$2K +$2.11K +106 +5,300%
QT
62
Quantbot Technologies
New York
$2K +$2.54K +128 New
CCMW
63
Cypress Capital Management (Wyoming)
Wyoming
$1.7K +$1.99K +100 New
TRCT
64
Tower Research Capital (TRC)
New York
$1K -$298 -15 -15%
WVP
65
Worth Venture Partners
New Jersey
$1K +$60 +3 +8%
WEC
66
Winslow Evans & Crocker
Massachusetts
$849 – – –
CAM
67
Cormorant Asset Management
Massachusetts
– -$10.1M -500,000 Closed
PA
68
Perceptive Advisors
New York
– -$5M -251,328 Closed
SFM
69
Sphera Funds Management
Israel
– -$2.01M -100,000 Closed
MWA
70
Marshall Wace Asia
Hong Kong
– -$1.65M -82,249 Closed
CCMU
71
Cheyne Capital Management (UK)
United Kingdom
– -$1.24M -61,762 Closed
IHM
72
Iguana Healthcare Management
New York
– -$1M -50,000 Closed
MCM
73
Moore Capital Management
New York
– -$704K -35,000 Closed
AAM
74
Auxier Asset Management
Oregon
– -$657K -32,699 Closed
PVI
75
Pura Vida Investments
New York
– -$603K -30,000 Closed
1 2
3
4

ZYNE Hedge Fund Activity: Q2 2017 in Review

66 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q2 2017, worth a combined $77M — up 9.3% from $70.5M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ZYNE positions and 20 closed out — a net gain of 6 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $9.17M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $10.1M sold.

  • 66 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q2 2017, up from 60 in Q1 2017.
  • Funds reported $77M of Zynerba Pharmaceuticals, Inc stock for Q2 2017, up 9.3% quarter-over-quarter.
  • 26 funds opened new Zynerba Pharmaceuticals, Inc positions in Q2 2017 and 20 closed out, a net change of +6 holders.
  • The largest Zynerba Pharmaceuticals, Inc buyer in Q2 2017 was BlackRock, an estimated $9.17M added.
  • The largest Zynerba Pharmaceuticals, Inc seller in Q2 2017 was Cormorant Asset Management, an estimated $10.1M sold.

Based on aggregated 13F filings for Q2 2017.